EP 265: How blood biomarkers are changing neurology diagnostics with Joe Volpe of Labcorp

EP 265: How blood biomarkers are changing neurology diagnostics with Joe Volpe of Labcorp

Title history
  • EP 265: How blood biomarkers are changing neurology diagnostics with Joe Volpe of Labcorp — observed on 20261112-1354 UTC (YouTube)
🎙 Joe Volpe 👥 1K 📅 November 12, 2026 ⏱ 45 min 👁 1 📄 expert opinion 🧭 2026-11-12
Available in: English (current) Français

Keywords

p-tau217APOEneurofilament lightAlzheimer's diagnosisblood-based biomarkers

Summary

In this episode of The Genetics Podcast, host Patrick Short interviews Dr. Joe Volpe, Executive Director at Labcorp, about the role of blood biomarkers in transforming neurology diagnostics. Volpe discusses the evolution from cerebrospinal fluid markers to blood-based tests, highlighting p-tau217 for Alzheimer’s disease as a scalable and accurate surrogate for amyloid pathology. He explains that p-tau217 is now widely used for triaging patients with mild cognitive impairment, though it is not diagnostic by itself. The conversation covers the use of APOE testing for risk assessment and its implications for anti-amyloid therapies, noting its predictive but non-definitive nature. Volpe emphasizes that Alzheimer’s diagnosis remains clinical, with biomarkers informing the assessment. He then explores emerging biomarkers for Parkinson’s disease and ALS, such as neurofilament light (NfL) and DDC, and discusses how Labcorp’s real-world data helps understand test utilization. The episode also addresses the challenges of early detection, the need for multi-drug approaches, and the potential for future migraine biomarkers. Volpe’s insights highlight the gap between laboratory discovery and clinical implementation, stressing the importance of scalable and accessible diagnostics.

177 words

Critical Evaluation

Value of the Information & Strength of the Argument

The interview provides valuable insights into the current state and future direction of blood-based biomarkers in neurology, particularly Alzheimer’s disease. Volpe supports his arguments with references to clinical trials and real-world data from Labcorp, including observations on p-tau217’s correlation with amyloid pathology and its limitations. He also addresses the controversy around the amyloid hypothesis and the need for further basic science. The argumentation is coherent and grounded in experience, though it occasionally relies on anecdotal points rather than specific published studies.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is moderate; while Volpe cites several studies and concepts, he does not provide specific citations or references to peer-reviewed papers, which limits verifiability. The sources mentioned are largely internal Labcorp data and well-known biomarkers, but the discussion lacks direct literature references. The title accurately reflects the content, as the episode focuses on how blood biomarkers are changing neurology diagnostics, with a clear emphasis on Alzheimer’s, Parkinson’s, and ALS. The alignment between title and content is strong.

175 words

Title / Content Match

The title accurately reflects the content: a discussion on how blood biomarkers are changing neurology diagnostics, focusing on Alzheimer's, Parkinson's, ALS.

Quality & Reliability

7/10

Interview with an industry expert, based on research and clinical experience, but no direct citations of peer-reviewed papers in the discussion.

Chapters

Contribution & Novelties

This episode provides a comprehensive overview of the current landscape of blood biomarkers in neurology, specifically detailing the practical aspects of implementing p-tau217 for Alzheimer’s screening. It offers unique perspectives from an industry expert involved in commercializing these tests, including real-world data on test usage. The discussion also highlights emerging biomarkers for Parkinson’s and ALS, and emphasizes the need for further basic research.

Pour aller plus loin :

  • Tau protein — Relevant to p-tau217, a phosphorylated tau protein used as a biomarker.
  • Apolipoprotein E — APOE gene’s role in Alzheimer’s risk and treatment considerations.
  • Neurofilament — NfL as a biomarker for neuronal damage across neurological diseases.

106 words

Radar Profile

The radar profile shows a balanced score across information quantity, quality, technical depth, and reliability, with a slight emphasis on information quantity and technical depth. This reflects an informative podcast that provides detailed insights into the science and clinical applications of biomarkers.

Reliability 7/10